TFF Pharmaceuticals, Inc. (0K3.F)
| Previous Close | 6.00 |
| Open | 6.05 |
| Bid | 5.60 x N/A |
| Ask | 5.80 x N/A |
| Day's Range | 6.05 - 6.05 |
| 52 Week Range | 6.00 - 16.60 |
| Volume | |
| Avg. Volume | 9 |
| Market Cap | 153.499M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.02 |
| Earnings Date | Mar. 08, 2022 - Mar. 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Simply Wall St.
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP): Are Analysts Optimistic?
We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the...
- GlobeNewswire
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients
Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic
- GlobeNewswire
TFF Pharmaceuticals Hosting Science Day on December 13, 2021
AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30p
